Archbold Memorial Hospital Adds Tru-D Robot to EVS Team
Archbold Memorial Hospital has added a layer of protection to complement its existing infection prevention strategies. The hospital recently implemented Tru-D SmartUVC—a UV disinfection robot—to help reduce the risk of hospital-acquired infections.
Once a room is cleaned using traditional cleaning methods, Tru-D is rolled in to complete the disinfection process. Standing at about 5 1/2 feet tall, the disinfection robot uses 28 ultraviolet bulbs to precisely deliver a measured UVC dose to disinfect hospital isolation rooms and surgical areas after use.
“Using an iPad outside the room, our staff turns on Tru-D remotely and begins a single disinfection cycle,” said Josh Moore, vice president of operations at Archbold. “The robot is able to compensate for room variables such as size, shape and contents to deliver the precise dose of UV energy needed throughout the entire room. The technology can clean an entire room, top to bottom, from a single location allowing our staff to perform other tasks during the disinfection process.”
During the disinfection cycle, Tru-D kills up to 99.9% of harmful pathogens in the room, including bacteria that cause infections in different parts of the body. Once the necessary amount of UV energy is reflected back to the robot, Tru-D automatically shuts down and notifies the operator via audio and/or text message that the disinfection cycle is complete.
“We are dedicated to providing the highest level of care for our patients and the safest health care environment possible for our staff and physicians,” said, Amy Griffin, vice president of patient care at Archbold. “Investing in Tru-D technology is a testament to that dedication and also to our continued commitment to implement innovative, state-of-the-art technology.”
Studies show that UV room cleaning strategies decrease the cumulative incidence of multidrug-resistant organisms. The first randomized clinical trial on UV disinfection, the Benefits of Enhanced Terminal Room Disinfection (BETR-D) study for which Tru-D was the only device chosen, will be published soon in The Lancet.
“Tru-D continues to be backed by sound science, and we are proud to be the only UV disinfection device chosen for and validated by the first-ever randomized clinical trial on UV disinfection,” said Chuck Dunn, CEO and president of Tru-D. “The researchers from the BETR-D study are encouraging hospitals to add enhanced disinfection technology to their infection prevention protocols. With the adoption of Tru-D, Archbold has taken that extra step to ensure patient safety and improve outcomes.”
Individual hospital results may vary based on numerous factors including adherence to standard disinfection protocol.